Results 21 to 30 of about 35,900 (152)

Drug‐induced liver injury associated with exposure to Hangeshashinto

Journal of General and Family Medicine, EarlyView.
While Kampo medicines are deemed relatively safe and associated with few adverse effects, primary care physicians are well advised to be aware of the risk of drug‐induced liver injury in patients prescribed Kampo medicines containing Scutellariae radix, such as Hangeshashinto, in clinical practice and to closely monitor their clinical course.
Kimitoshi Kubo, Issei Ashida, Noriko Kimura   +2 more
wiley   +1 more source

Clinical Images: Acute vision loss due to granulomatosis with polyangiitis

Arthritis &Rheumatology, EarlyView.
Hirotaka Yamamoto, Yoshinori Taniguchi
wiley   +1 more source

Trends in resource utilization for new‐onset psychosis hospitalizations at children's hospitals

Journal of Hospital Medicine, EarlyView.
Abstract Background Children with new‐onset psychosis often require hospitalization for medical evaluation. Objectives The goal of this study was to assess variations in the management of children with new‐onset psychosis and characterize trends in resource utilization.
Ankita Gupta, Matt Hall, Benjamin Masserano, Averi Wilson, Katherine Johnson, Clifford Chen, Lasya Challa, Harita Katragadda, Vineeta Mittal   +8 more
wiley   +1 more source

Treatment of Pyoderma Gangrenosum With Bimekizumab

JEADV Clinical Practice, EarlyView.
ABSTRACT Pyoderma gangrenosum (PG) is an inflammatory neutrophilic dermatosis with no FDA‐approved treatments. Current therapies, including corticosteroids and immunomodulators, often show limited efficacy and nonspecific, conferring to higher risk of adverse events.
Kareena S. Garg, Adeel Ahmad, Leonardo Tjahjono   +2 more
wiley   +1 more source

COLLAB: A Global Survey of Clinical and Laboratory Assessment in Alopecia Areata by Hair Specialists

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Alopecia areata (AA) is a common non‐scarring alopecia. Data continue to emerge on associations with autoimmune and other conditions. Janus kinase inhibitors (JAKi) are increasingly used to treat AA. Objectives The aim was to assess variation in laboratory testing in patients with AA among hair experts internationally and to compare
Cathal O'Connor, Aoife Boyle, Leila Asfour, Bevin Bhoyrul, Laita Bokhari, George Cotsarelis, Chantal Cotter, Brittany Craiglow, Lara Cutlar, Rachita Dhurat, Ncoza Dlova, Isabella Doche, Jeff Donovan, Aaron M. Drucker, Samantha Eisman, Daniel Fernandes Melo, Matthew J. Harries, Maria Hordinsky, Ahmed Kazmi, Brett King, Antonios Kolios, Nekma Meah, Paradi Mirmirani, Arash Mostaghimi, Manabu Ohyama, Yuliya Ovcharenko, Rodrigo Pirmez, Bianca Maria Piraccini, Lidia Rudnicka, David Saceda‐Corralo, Jerry Shapiro, Cathryn Sibbald, Rod Sinclair, Blake R. C. Smith, Michela Starace, Sergio Vaño‐Galván, Wei Liang Koh, Katherine York, Ian McDonald, Dmitri Wall   +39 more
wiley   +1 more source

Efficacy of High‐Dose Intravenous Anakinra in Pediatric TAFRO Syndrome: Report of Two Cases and Literature Review

Pediatric Blood &Cancer, EarlyView.
ABSTRACT TAFRO (thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly) syndrome is a rare, life‐threatening inflammatory condition linked to infections, neoplasms, and idiopathic multicentric Castleman disease. Interleukin (IL)‐6 inhibitors are the primary treatment, but refractory cases require alternatives. This
Serena Palmeri, Jacopo Ferro, Valentina Natoli, Caterina Matucci‐Cerinic, Riccardo Papa, Silvia Rosina, Stefania Sorrentino, Stefano Volpi, Valerio Gaetano Vellone, Marco Gattorno, Roberta Caorsi   +10 more
wiley   +1 more source

Immune cell alterations in a pristane‐induced lupus model in C57BL/6J mice

Rheumatology &Autoimmunity, EarlyView.
A pristane‐induced systemic lupus erythematosus model was established in C57BL/6J mice. Mice were randomly assigned to a pristane group (0.5 mL pristane intraperitoneally) or a control group (0.5 mL saline intraperitoneally). Six months later, levels of antinuclear antibodies, serum inflammatory cytokines, urinary protein, renal injury, and immune cell
Yali Zhou, Binbin Yang, Haojun Long, Qinghuan Zhu, Yongzhuo Wu, Yingying Liu, Limei Yuan, Wenting Cao, Xinwei Huang, Danqi Deng   +9 more
wiley   +1 more source

Avoiding early diagnosis

Journal of General and Family Medicine, EarlyView.
Takao Wakabayashi, Goh Keng Wee, Mikinosuke Ishibashi, Yoshiki Akiyama, Naoki Kanda, Tomoyuki Watanabe   +5 more
wiley   +1 more source

Treatment strategy for systemic lupus erythematosus using belimumab as indicated by multi‐omics analysis

Rheumatology &Autoimmunity, EarlyView.
Recent multi‐omics studies have demonstrated that belimumab specifically targets naïve B cells and a subset of memory B cells. This observation is consistent with belimumab's established efficacy and safety profile. Abstract Belimumab is an antibody targeting the cytokine B‐cell activating factor (BAFF), which is crucial for B cell differentiation, and
Keishi Fujio, Toshiyuki Ushijima, Tatsuki Abe, Tomohisa Okamura, Sang‐Cheol Bae, Yumi Tsuchida   +5 more
wiley   +1 more source

Upper extremity deep vein thrombosis associated with systemic lupus erythematosus and antiphospholipid syndrome

Journal of General and Family Medicine, EarlyView.
Masahiro Yabe, Nozomi Ozaki, Nobuhiro Sato, Norihito Nakamura, Azusa Aoyama, Shuichi Murakami, Yasuo Hirose   +6 more
wiley   +1 more source